Speakers

Mr. Robert Andersson

Chief Executive Officer & President | Oriola

Mr. Andersson was appointed Oriola Corporation´s President & CEO effective February 12, 2018. He joined Oriola from Telia Company where he held several senior roles including Senior Vice President and Head of Corporate Holdings, Executive Vice President and Head of Region Europe, and President and CEO of TeliaSonera, Finland. He was a member of Telia Company’s Group Management since 2012. Prior to Telia Company, Mr Andersson held several international managerial and executive positions within Nokia, including serving on Nokia’s Group Executive Board 2005-2009 as Executive Vice President Customer and Market Operations and Executive Vice President Devices Finance, Strategy and Sourcing.

Dr. Stefan Biesdorf

Partner | McKinsey & Company

Dr. Stefan Biesdorf is a Partner of McKinsey & Company and based in Munich. He is a member of McKinsey's Digital Office and serves clients from the Healthcare Sector on Digital and technology-related topics. He is leading McKinsey’s European Digital Health System & Services Practice. He has published several articles and regularly gives speeches on Digital Health.
Stefan Biesdorf holds a Graduate degree in Physics from the University of Munich and a PhD in Neuroscience. He studied Marketing and Microeconomics at NYU.

Dr. Karl Broich

President | Federal Institute for Drugs and Medical Devices (BfArM)

Prof. Dr. med. Karl Broich absolved a Study of Human Medicine at the Medical Faculty of the Rheinische-Friedrich-Wilhelms-Universität Bonn.
Since 2014, Karl Broich is President of the Federal Institute for Drugs and Medical Devices in Bonn.
His current activities in the European network of regulatory authorities are member of the European Medicines Agency’s Management Board (EMA MB) and Chair of the EU Telematics Management Board (EU TMB). In addition, he is member of the Heads of Medicines Agencies (HMA) Management Group. His scientific focus is clinical psychopharmacology; advanced imaging in neurodegenerative diseases, biomarkers, dementia, and methodology of clinical trials. In addition, Karl Broich is author and co-author of over 180 essays (original scientific papers, reviews, book contributions).

Mr. Matthias Dalkner

Director Sales Healthcare Solutions | KNAPP AG

Matthias Dalkner was appointed KNAPP AG’s Sales Director for their Healthcare Business Unit in 2016. In his global role, he is responsible for the Account Management of KNAPP’s largest customer base, which is pharmaceutical wholesale, as well as the Business Development in all healthcare sectors. Having been with KNAPP for 18 years, he has not only gained profound knowledge of warehouse automation but also of the intricacies of the pharmaceutical supply chain. Matthias has a Master of Arts in Business from CAMPUS 02 University of Applied Sciences in Graz.

Mr Chip Davis

President and Chief Executive Officer | Healthcare Distribution Alliance (HDA)

Chester “Chip” Davis, Jr., JD, is the President and Chief Executive Officer of HDA and President of the HDA Research Foundation. Mr. Davis joined HDA in March 2020 from the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers of generic and biosimilar medicines, where he served as President and Chief Executive Officer since 2015. Mr. Davis oversees HDA’s day-to-day operations and is responsible for ensuring that the organization’s members have a strong advocacy voice in legislation, regulation and policy.
Prior to AAM, Mr. Davis held leadership roles at the Pharmaceutical Research and Manufacturers of America and AstraZeneca, where in 2007 he was recognized as one of the inaugural winners of the CEO Leadership Award.
Mr. Davis earned an undergraduate degree in Accounting from the University of Delaware, and a Juris Doctor from the University of Baltimore School of Law.

Mr. Guillaume Dedet

Health Economist and Policy Analyst | OECD

Guillaume Dedet is a health economist and policy analyst at the OECD health division. He co-leads the work around the "State of Health in the EU" cycle. Guillaume is a public health physician (MD in Public Health from the Greater Paris Academic Hospital) and holds additional post-graduate degrees in statistics (MSc from University Paris-Sud), health economics (MSc from LSE) and diplomacy (MA from SOAS). Prior to joining the OECD, Guillaume served as a technical officer in the Division of Health Systems and Public Health at the WHO Regional Office for Europe and as senior advisor in the Health Financing Division of the French Ministry of Health.

Ms. Monika Derecque-Pois

Director General | European Healthcare Distribution Association (GIRP)

Monika Derecque-Pois was born in Graz/Austria and holds a master’s degree in Economics from the University of Economics in Vienna, where she specialised in International Trade and Marketing.
Ms. Monika Derecque-Pois is the Director General of GIRP, the European Healthcare Distribution Association, which brings together over 750 pharmaceutical full-line wholesaling companies and their national associations from 35 countries. Monika was appointed to her current position in 2001, having previously served as European affairs consultant for GIRP. She has over 20 years of experience in European public affairs.
Prior to her engagement with GIRP, she served as a director in a European affairs consultancy company and she also held a six-year post as Marketing and Client Support Manager at IMS Health Austria.

Mr. Bernd Grabner

President | EUROPEAN HEALTHCARE DISTRIBUTION ASSOCIATION (GIRP)

Mr Bernd Grabner is Member of the board of Jacoby GM Pharma and Vice-President of PHAGO, the Austrian Association of Pharmaceutical full-line Wholesalers. He has also been Member of the GIRP Board since June 2015.

Mr Grabner started his studies in law and business economics in Linz in 1993. While still studying, he worked in the family-owned wholesaling company, where he was in charge of a wide range of operational tasks.

Mr Grabner became member of the board of GM Pharma in 2003. Since the merger with Jacoby Pharmazeutika in July 2013, he has been member of the board of Jacoby GM Pharma and therein responsible for the division supplier relations, key account management for dispensing doctors and new business activities.

Dr. Hans-Walter Höhl

Consultant | hwh Digital Consulting Pharmaceutical Operations & Supply Chain Management

Hans-Walter has a broad background in pharmaceutical operations, supply chain management, manufacturing strategy and operational excellence. He recently retired from Bayer AG as Senior VP of Strategic Projects. He was responsible for defining the digital manufacturing strategy and executing the digital transformation at key sites and functions. The experiences gathered at a digital pilot site were acknowledged as Digital Lighthouse Factory by the World Economic Forum in 2019. Hans-Walter provides consulting services in the fields of pharmaceutical manufacturing, supply chain and their digital transformation.

Mr. Kai Kaasalainen

Chief Executive Officer | Tamro Corporation

Kai Kaasalainen is a Finnish business leader and Managing Director of the pharmaceutical wholesaler and service company Tamro Corporation in Finland.

He has been working more than 10 years in Tamro and before that more than 20 years in high tech companies in the Retail sector.
He is also well known as an influencer, public speaker, blogger and he was rewarded the Finnish “Thought leader of the year 2018” title.

Mr. Kevin Kettler

Chairman of the Management Board and President of McKesson International | McKesson Europe AG

Kevin Kettler is Chairman of the Management Board and President of McKesson International. In this role, he is responsible for leading the company’s businesses in 13 European countries.
Previously, Kettler was President of McKesson Global Procurement and Sourcing in London. There, he led McKesson’s global pharmaceutical procurement program as well as international teams responsible for growing McKesson’s private label generics portfolio, NorthStar, and the globally-sourced medical surgical portfolio.

Prior to this role, Kevin Kettler was Senior Vice President of Marketing for McKesson U.S. Pharmaceutical (US Pharma). During his time in this role, he had accountability for market strategy, product development and customer programs for all customer market segments of the US Pharma business; he also had direct responsibility for four standalone businesses: AccessHealth, McKesson Patient Relationship Solutions, Macro Helix and Supplylogix. For Supplylogix and Macro Helix, he led the acquisition and post-acquisition growth of the businesses.
Kevin Kettler previously held various roles in McKesson’s Corporate Strategy and Business Development group including Senior Vice President of Corporate Strategy and Business Development supporting US Pharma. He was responsible for developing the overall strategic and market direction for the US Pharma business. On the business development side, he evaluated, negotiated and assisted in the integration of acquisitions.

Prior to his role in Corporate Strategy and Business Development, Kevin Kettler was a consultant to McKesson leading the integrations of acquired businesses into McKesson systems and processes.
Before McKesson, Kettler held various product marketing, product management and consulting roles in early stage start-ups. Prior to this, he was a materials supervisor for a medical device company now owned by Siemens, and he began his career as a project engineer for Amoco Oil.

Kevin Kettler, born in Michigan, USA, holds an MBA from the University of North Carolina, Chapel Hill and a BS in Mechanical Engineering from the University of Notre Dame.

Mr. Admir Kulin

Managing Director | m.Doc GmbH

Admir Kulin began his career in the nineties as a professional basketball player and coach, while at the same time studying business administration in Koblenz. After working as a controller in sports management and as an IT project manager at Nürburgring Automotive, he joined vitaphone, a telemedical service provider. There he held various positions, including CFO and member of the board. Subsequently, Kulin, today's specialist for digital health with a strong focus on digital platforms, founded m.Doc GmbH, which he has headed as managing director to date.

Ms. Stella Kyriakides

European Commissioner for Health and Food Safety | European Commission

Stella Kyriakides, born in 1956, is a medical psychologist and member of the Cypriot Christian-democratic party (DISY), holding the position of Vice-president since 2013. In October 2017, she was elected President of Parliamentary Assembly of the Council of Europe until January 2018. Before joining politics, she worked for 27 years at the Ministry of Health of Cyprus in the department of Child and Adolescent psychiatry. In addition to her parliamentary activities, in 1999, Kyriakides was appointed as the President of the First Breast Cancer Movement in Cyprus and, in 2016, as President of the National Committee on Cancer Strategy of the Council in 2016.

She will have increased attributions compared to her predecessor, as she will oversee the regulation of medical devices and pharmaceuticals, previously under the competence of the Internal Market and Industry Commissioner. This means that Directorate responsible for Health (SANTE) is consolidating authority over health policy with the two units responsible for medical devices and pharmaceuticals being moved to SANTE in the upcoming Commission.

With increased powers, Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innovation.
As stated in her mission letter drafted by President-elect Ursula von der Leyen, she is expected to present a legislative proposal for a new regulatory framework on medical devices, with the aim of protecting patients. The other biggest issue of her mandate is the preparation of Europe’s Beating Cancer Plan, which is supposed to be a support tool for member states to improve national cancer prevention and care systems.

Mr. Doug Long

Vice President Industry Relations | IQVIA

Doug Long is Vice President of Industry Relations at IQVIA, the world’s largest pharmaceutical information company. Doug has been with IMS since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.

Although well versed in the global pharmaceutical market, the heart of Doug’s Industry year review is that of trends and forecasts in the US. Doug is current on topics such as mergers and acquisitions, tiered co-pay, generics, biologics, PBM’s and other emerging channels, and is also an expert on the complex issue of patient privacy.

Doug was honored with the 2004 HDMA Nexus Award for lifetime achievement and received IMS’s prestigious Summit award in 2003.

Prior to IMS HEALTH, Doug was at Nielsen Market Research for sixteen years in various sales and marketing capacities. A native of Illinois, Doug received a BA degree from the DePaw University in Greencastle, Indiana, and an MBA in Management from Fairleigh Dickinson University in New Jersey.

Ms. Agnès Mathieu-Mendes

Deputy Head of Unit, Medical products: quality, safety, innovation | DG SANTE, European Commission

Agnès Mathieu-Mendes is Deputy Head of the unit dealing with the quality, safety and innovation of medicinal products in the Directorate General on Health and Food Safety in the European Commission. Her responsibilities include the implementation of the Falsified Medicines Directive, the Clinical Trials Regulation, Good Manufacturing Practices, Good Distribution Practices and mutual recognition agreements on GMP with third countries. She has been working for many years in the pharmaceutical field notably with the authorisation process of medicinal products or the orphan medicinal products.

Agnès joined the European Commission in 2006 to work on the Better Regulation agenda of the Directorate General for Enterprise and Industry.

She is a pharmacist by training and has a diploma in pharmaceutical engineering and industrial technology. Prior to the European Commission, Agnès held positions in the pharmaceutical industry and in the Council of Europe.

Mr. Darragh O'Loughlin

Secretary General | Irish Pharmacy Union (IPU)

Darragh O’Loughlin is Secretary General of the Irish Pharmacy Union (IPU), the professional representative and leadership organisation for community pharmacists in Ireland. He is also a former President of the IPU as well as a former President of PGEU, the pan-European community pharmacy organisation.

Darragh has experience in both hospital and community pharmacy and has operated his own pharmacies in the west of Ireland for almost 20 years. He received Bachelor’s and Master’s Degrees from Trinity College Dublin and has also gained qualifications from the Institute of Commercial Management and Henley Business School in the UK.

Darragh has wide experience of regulation, quality standards and professional development in pharmacy and healthcare, having previously been appointed by successive Ministers for Health to both the Council of the Pharmaceutical Society of Ireland (PSI) and the Board of the Health Information & Quality Authority (HIQA).

Darragh advocates consistently for a greater recognition of the contribution that community pharmacists make to patient health and for an expansion of the role of pharmacists in delivering convenient, accessible and cost-effective healthcare for the benefit of patients, the public and the health system.

Mr. Peter O’Donnell

Journalist |

Peter O’Donnell is a Brussels-based journalist who has been covering European affairs for more than twenty years. He has worked for The Financial Times, The Sunday Times, Reuters, the Economist Intelligence Unit, UPI, Euronews, and many other media in Europe and beyond, covering all aspects of EU affairs, and conducting television interviews with leading EU figures on issues of the moment. He is a former editor-in-chief of Europe Information Service, and a former associate editor of European Voice and of POLITICO. He is Brussels correspondent for APM Health Europe and European columnist for Applied Clinical Trials. In addition to his work as a journalist, he acts as editor, editorial adviser and speechwriter for numerous clients in the corporate, political and academic world, and has conceived, created and authored numerous publications for the EU institutions and corporate clients. He frequently acts as moderator or chairman in European-level conferences and debates on a wide range of EU-related subjects, at all levels from informal ministerial meetings to specialised seminars and working groups, on subjects ranging from health to ICT, and from foreign affairs to energy.

Ms. Florina-Andreea Pantazi

Legal Officer - Free movement of goods – Single Market Policy, Mutual Recognition and Surveillance | DG GROW, European Commission

Andreea Pantazi works since March 2019 as a legal officer responsible for the implementation of Articles 34-36 of the Treaty on the Functioning of the European Union (free movement of goods) in the European Commission, Directorate General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW). Between 2016 and 2019 Andreea Pantazi worked as a legal officer responsible for mutual recognition in the field of goods, and developed Regulation (EU) 2019/515 on the mutual recognition of goods lawfully marketed in another Member State. Between 2013 and 2016, Andreea Pantazi was a policy officer responsible for market surveillance. Between 2009 and 2013, Andreea Pantazi was responsible for the implementation of the Toy safety legislation. Prior to joining the European Commission, she worked for the Chamber of Commerce and industry in Toulouse, France, in charge of European affairs. Andreea Pantazi is a graduated of the University of Toulouse, France, European law school.

Mr. Torsten Roos

General Manager | INSIGHT Health

Torsten Roos is General Manager at INSIGHT Health, the German based information and big data provider. He is member of the executive board and responsible for the expansion of international data panels, strategic alliances with data suppliers/partners and the development of new data strategies.
Before taking over this responsibility, he joined the former NDC Health in 2000 and implemented the company`s product portfolio for wholesalers and pharmacies. Till 2008 he served INSIGHT Health as director data source in Germany. During the international expansion of INSIGHT Health in the last years, Torsten established the company as strategic partner for wholesaler, retailers and pharmaceutical traders in Europe and managed the expansion in new data panels in several European countries.
Due to his functions and career, Torsten is an expert in Health Care Data and digital data contents. Torsten studied social science at Justus-Liebig-University, Gießen and University RheinMain, Wiesbaden and holds an MBA of the FOM University, Essen.

Mr. Duarte Santos

Member of the Board, Portuguese Pharmacy Association (ANF) | President, PGEU

After having completed the Integrated Master´s Degree in Pharmaceutical Sciences of the Faculty of Pharmacy of the University of Coimbra in 2008, Mr Santos acquired a Pharmacy in Lisbon. Over the first nine years of his career, Mr Santos has experienced and took on the responsibilities of functions of both technical direction and management of
the Pharmacy.

Mr. Santos became resident of the Portuguese Young Pharmacists Association from 2011 to 2015. In May 2013, Mr Santos became a member of the board of ANF, and has held diverse functions of direction and management of different departments and projects. International representation of ANF and the institutional relations with the Academy and the Student´s Associations, are also part of his assigned responsibilities at ANF.

Since 2014, Mr Santos is an invited professor at the Faculty of Pharmacy of the University of Lisbon. Director of the Magazine “Farmácia Portuguesa”, since April 2016. Mr Santos is an MBA graduated by AESE Business School, in Lisbon. Is the President of the Pharmaceutical Group of the European Union.

Mr. Alfredo Sassi

Founder | H-Ventures

Alfredo Sassi is CEO and Founder of H-Ventures Group, an Italian family holding that controls and participates in several other Companies with core business always related to the Healthcare Sector. In particular, through its American sister Company ATLAS based in New York, H-Ventures internationally delivers market-leading solutions in the fields of IoT, AI, Deep Learning, Big Data, Digital Signage and Digital Engagement.

As an innovative and disruptive entrepreneur, Alfredo Sassi always devoted a lot of energy in creating and promoting groundbreaking solutions. With this vision, H-Ventures has become a Founding Member of MIND - Milan Innovation District (ex Area Expo Milan 2015). In particular, within MIND’s Federated Innovation Community, he has worked, side by side with other international top players, on the definition of an innovative and ‘smart’ concept for the Healthcare Sector, as well as on the development of other important areas in this forward-looking neighborhood of Milan, where H-Ventures also leads the Project for the Retail Tech Sector.

Several are the managerial and institutional roles Alfredo Sassi took on throughout his business career. He is a Member of ASSORAM’s Board of Auditors (Italy’s National Association of Pharmaceutical Pre-Wholesalers) and also Member of its IT Committee. Alfredo Sassi is also Contract Professor in “Big Data and Computational Models for Marketing” for the Academic Year 2020/2021 at the University of Pavia. For over 20 years he has worked as Managing Director of important Pharmaceutical Wholesalers Groups and has held representative roles in the major national and European category associations. To name but a few, he was Vice President of ADF and sat in several GIRP Committees representing SECOF.

Mr. Martin Sawer

Executive Director | Healthcare Distribution Association UK (HDA UK)

Martin was a government official for 7 years, including nearly 3 years in the office of the UK Prime Minister.

At HDA, Martin is responsible for the mission and all operations of the Association, which has included a Government minister’s launch of the HDA ‘Gold Standard of Good Distribution Practice’ in the UK Parliament, and the constant engagement of stakeholders, regulators and policymakers on many NHS and healthcare issues. In 2016, the launch of the re-named Healthcare Distribution Association emphasised the Association’s desire to embrace medicines supply developments and restate the value of the sector. In 2020, through the HDA, the UK’s medicines distribution sector has been able to more publicly demonstrate its value to the UK’s healthcare system in the fight against Covid, which has been recognised by the UK Government. Martin also represents the sector on the board of SecurMed UK, the UK’s national medicines verification organisation.

Mr. Andy Sloman

Managing Director | LloydsPharmacy

Andy is a Med-Tec expert who has led the expansion and growth of LloydsPharmacy Online Doctor over the last six years.
He previously led the development of market leading mobile banking systems in his roles as CTO and R&D Director in the retail finance industry.
Andy has pioneered the development of automated prescribing through the use of sophisticated clinical algorithms which deliver massive scalability, consistent quality and can improve patient outcomes.

Dr. Roger Sorel

Vice President | European Healthcare Distribution Association (GIRP)

Dr. Roger Sorel studied at the University of Utrecht where he graduated in Pharmacy in 1977 and graduated with a Doctor of Science degree in 1982. He has since been working as a pharmacist at a health care insurer, and from 1989 he has held management positions at pharmaceutical wholesalers. He also followed management training at INSEAD, Fontainebleau, France.

From 1 April 1997 until 1 February 2010, Dr. Sorel was Managing Director of Brocacef Holding NV for 12 years. From 1 August 2010 until August 2020 Dr Sorel was member of the Supervisory Board of Brocacef Groep NV, which is now a 55/45 joint venture between Phoenix Pharmahandel GmbH & Co KG and McKesson Europe AG. For many years, he was the Chairman of the Dutch Pharmaceutical Wholesale Association (BG Pharma). He still represents BG-Pharma in GIRP where he is Vice President for the smaller and mid-sized countries.

In the pharmaceutical area, he is the Chairman of the Foundation SIR Institute for Pharmacy Practice and Policy.
Besides the pharmaceutical business, he is the Chairman of the Dutch General Wholesale Association (NVG) and Board member of the Dutch Employers Organisation (VNO-NCW).

Ms. Jurate Svarcaite

Director General | Association of the European Self-Medication Industry (AESGP)

As Director General, Ms Svarcaite is responsible for providing strategic direction and leadership while managing the day to day operations of Association of the European Self-Medication Industry (AESGP) and its ongoing relationships with its member associations, companies and other stakeholders, as well as representing the self-medication industry in various International, European and national forums. The Association of the European Self-Medication Industry (AESGP) represents the manufacturers of non-prescription medicines, food supplements and self-care medical devices in Europe, an area also referred to as consumer healthcare products.

Her previous work experience includes the Secretary General position at the Pharmaceutical Group of the EU (PGEU), an umbrella organization representing community pharmacy in Europe. Before that she managed Pharmaceutical Care Department in a major pharmacy chain in Lithuania. Among other tasks she was responsible for development and implementation of new pharmacy services and professional development of pharmacy staff. She also worked for 3 years at the PGEU as Pharmaceutical and Professional Affairs Advisor; she was responsible for technical dossiers relevant to pharmacy practice (eg, pharmacovigilance, falsified medicines, medical devices) and activities and policy on patient safety, environment, pharmaceuticals, and education. Prior to her work at PGEU, Ms. Svarcaite was Project Coordinator at The School of Pharmacy, University of London, where she researched and developed competency frameworks that supported pharmacy practitioners and helped to maintain their fitness to practice at all levels.

Ms. Svarcaite received her Master in Pharmacy degree from Kaunas University of Medicine, Kaunas, Lithuania. She spent her fourth year in the Erasmus Exchange Program at Università degli Studi di Parma, Parma, Italy, where she studied cosmetics and nutrition, Italian pharmaceutical legislation, toxicology, and innovative pharmaceutical forms. She went on to earn her Master of Science degree in Pharmacy Practice from The School of Pharmacy, University of London. Her thesis, "Surveying Pharmacy Practice in Europe," was an exploratory primary research study that surveyed the perceived relevance of practice-based competencies among pharmacy students and recently registered practitioners in different European countries.

Ms. Svarcaite began her career as a Community Pharmacist. A fluent speaker of Lithuanian and English with skills in Italian and Russian, she has presented at numerous workshops and conferences as invited speaker, facilitator, and/or chair.

Mr. Per Troein

Vice President Strategic Partners | IQVIA

Per Troein has been with IQVIA for 19 years and is responsible for the relationship with suppliers and associations. The dispensing and distribution environment is very dynamic. Pricing of pharmaceutical is as complicated. He also has deep insight around generics and biosimilars and how they are handled in different markets. One of IQVIA’ priorities is to have the best understanding of those dynamics to secure the most appropriate data, to be the best partner with the different data partners, and to be able to support the industry and also when appropriate governments. He is a well know speaker in the field of distribution trends and pricing and is very active in consulting projects in the area.

Prior to joining IMS, Per worked 13 years for Pharmacia in US and Europe. His last 6 years were spent in strategic development as a VP including several major mergers and acquisitions.

He holds an MSc in engineering from Lund’s Institute of Technology and an MBA from INSEAD.

Mr. Noël Wathion

Deputy Executive Director | European Medicines Agency (EMA)

Noël Wathion is the Deputy Executive Director of EMA (European Medicines Agency) since 1 February 2016. He also exercises the function of Chief of Policy. He is the Chair of the EMA ORP (Operations and Relocation Preparedness) Task Force, set up since June 2016 following the United Kingdom’s decision to leave the European Union, responsible for overseeing all Brexit consequences for the Agency and coordinating the Agency’s response, including the Agency’s relocation from London to Amsterdam. He is also the Chair of the Agency’s COVID-19 Steering Group, set up in March 2020 to coordinate the Agency’s activities related to the COVID-19 pandemic, hereby ensuring EMA’s preparedness for any possible scenario during the pandemic.
He joined the Agency in August 1996 and was appointed over the past 20 years to several senior managerial positions. He is a qualified pharmacist from the Free University of Brussels (VUB).

Mr. Marc Werner

Chief Executive Officer | Galenica

Marc Werner was born in Switzerland, and started his career as a Federal certified marketing director. He followed various management training courses at the International Institute for Management Development (IMD) in Lausanne, London Business School and Harvard Business School.
In 1990, he became Head of Sales at Sinome Ltd (Zellweger Uster Ltd). He then became Head of Product Management Photofinishing at the Federation of Migros Co-operatives before joining Minolta Ltd as Head of Marketing and Sales and later becoming Head of Marketing and Sales at Bluewin Ltd.

Marc joined the Swisscom Group in 2005 as head of Marketing & Sales at Swisscom Ltd, was head of Service from 2012 to 2013, member of the Group Executive Board from 2013, head of Private Customers until 2015 and head of Sales & Services from 2016 to 2019. Since 2020, Marc Werner has been the CEO and member of the Corporate Executive Committee of the Galenica Group.

Dr. Christa Wirthumer-Hoche

Head, Austrian Medicines and Medical Devices Agency | Chair, European Medicines Agency (EMA) Management Committee

DI Dr. Christa Wirthumer-Hoche studied biochemistry and graduated at the Technical University, Vienna in 1981, she did her doctoral thesis at the Institute for Medical Physiology, graduating in 1983. After joining the Austrian National Institute for Quality Control of Drugs (1983 – 1998), she was the Head of the Licensing Division for medicinal products, in the Unit for Pharmaceutical Affairs at the Austrian Federal Ministry of Health and Women.
Since foundation of the new Austrian Agency 1 January 2006 her position was Head of the Unit for Marketing Authorisation and Lifecycle Management of Medicinal Products, her current position is Head of the Austrian Medicines and Medical Devices Agency at AGES Austrian Agency for Health &Food Safety.
Since 1994 she has been a member in several European Committees and Working Parties, and she is currently appointed Chair of the EMA-Management Board.

Mr. Hannes Woerner

Global Head Supply Chain | Sandoz

Hannes Woerner was born in Innsbruck, Austria and studied Business Administration at Vienna University of Economics and Business. He holds an Executive MBA degree from ETH Zürich.
Hannes joined Novartis in 2003 in Sandoz Austria. He held Supply Chain roles with local, regional, and global responsibility including Supply Chain Head Anti-Infectives and Head Supply Chain for Sandoz Germany. He most recently became Global Head Supply Chain for Sandoz in Switzerland.

You are here